NASDAQ$HLVX
HilleVax Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2023 and highlighted recent company progress.
HilleVax reported its financial results for the second quarter of 2023. The company had cash, cash equivalents and marketable securities totaling $244.1 million as of June 30, 2023. Net loss for the second quarter 2023 was $27.9 million, compared to $53.9 million for the second quarter 2022.
- Completed enrollment of the NEST-IN1 Phase 2b clinical trial with over 3,000 subjects enrolled in six countries.
- Appointed Nanette Cocero, Ph.D., MBA, to its Board of Directors.
- Topline safety and clinical efficacy data from NEST-IN1 is expected in mid-2024.
- Cash, cash equivalents and marketable securities totaled $244.1 million as of June 30, 2023.
Headline financials
Revenue & EPS history
HilleVax · Revenue · Quarterly
$0
Forward guidance
HilleVax expects topline safety and clinical efficacy data from NEST-IN1 in mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
-3.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
22%
4 / 18 earnings
Positive
+7.9%
Q4 2024
Best reaction
-16.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.5% | +0.5% | +2.0% | |
| Q1 2025 | -1.0% | -5.6% | -6.7% | |
| Q4 2024 | +7.9% | -10.1% | +17.0% | |
| Q3 2024 | -2.6% | +1.6% | +2.6% | |
| Q2 2024 | -0.6% | +5.7% | +8.2% | |
| Q1 2024 | +2.7% | -3.0% | +0.2% | |
| Q4 2023 | -9.0% | -5.4% | -29.5% | |
| Q3 2023 | +1.5% | — | — | |
| Q2 2023 | -16.7% | — | — | |
| Q1 2023 | -1.2% | — | — | |
| Q4 2022 | -12.1% | — | — | |
| Q3 2022 | -8.2% | — | — | |
| Q3 2021 | -8.2% | — | — | |
| Q2 2021 | -6.5% | — | — | |
| Q2 2022 | -6.5% | — | — | |
| Q1 2022 | +0.0% | — | — | |
| Q1 2021 | +0.0% | — | — | |
| Q4 2021 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro